

S.I. 2011 No. 73

Drug Service Act
Cap. 40A

**DRUG SERVICE (BARBADOS NATIONAL DRUG
FORMULARY) (APPROVAL) ORDER, 2011**

The Minister, in exercise of the powers conferred on him by section 5(3) of the *Drug Service Act*, makes the following Order:

1. This Order may be cited as the *Drug Service (Barbados National Drug Formulary) (Approval) Order, 2011*.
2. The 30th Edition of the Barbados National Drug Formulary is approved for publication.
3. The items set out in
 - (a) Part I of the *Schedule* are approved for removal from the Barbados National Drug Formulary and shall not be included in the 30th Edition of the Barbados National Drug Formulary; and Schedule.
 - (b) Part II of the *Schedule* are approved for inclusion in the 30th Edition of the Barbados National Drug Formulary and shall be inserted into the 30th Edition of the Barbados National Drug Formulary. Schedule.

SCHEDULE

(Paragraph 3)

PART I

(Paragraph 3(a))

*Drugs not included in the 30th Edition of the
Barbados National Drug Formulary*

1. ACIPIMOX

Therapeutic Category: Antihyperlipidemic analogue of Niacin.

Indications: Treatment of hypertriglyceridemias.

Caution/Side Effects: Flushing, gastric upset and headache. Vomiting, hypotension, heartburn, loose stools and rash have also occurred.

Dose Range: Adult: 250mg 2-3 times daily or 500mg once daily.

Preparations:

Capsule, 250mg

Consult the BDS for Supplies. (No Offers to Supply)

Adrenaline 1% 10ml eye drops

2. ADRENALINE

Indications: Primary open angle and secondary glaucoma. May be used with miotic, beta blocker or carbonic anhydrase inhibitor therapy.

Caution/Side Effects: Do not use in narrow or shallow angle glaucoma. Discard one month after opening bottle. Do not use if solution has become dark amber. May cause macular oedema in post cataract surgery patients. Discolors contact lenses.

WADA Status: Banned in competition.

SCHEDULE - Cont'd

(Paragraph 3)

PART I - Cont'd

(Paragraph 3(a))

Dose Range: Instil 1 drop into eye 1 - 2 times daily.

Preparations:

Eye drops, 1%; 10ml

Consult the BDS for Supplies. (No Offers to Supply).

3. AMLODIPINE/VALSARTAN(B)

Therapeutic Category: Antihypertensive

Indications: Hypertension

Caution/Side Effects: Exercise caution in patients with acute myocardial infarction, cardiac dysrhythmia and kidney disease. Do not use in patients with congestive heart failure, myocardial infarction, obstructive coronary artery disease or in pregnancy; risk of injury and even death to the developing fetus. Side effects include hypotension, peripheral edema, flushing, dizziness, headache, cough, nasopharyngitis, upper respiratory infection, fatigue, acute myocardial infarction (rare) cardiac dysrhythmia, kidney disease. Dosage adjustments may be required in the following cases: hepatic impairment: lower initial doses of amlodipine may be required. Geriatric: lower initial doses of amlodipine may be required. Renal impairment: dose adjustment is not necessary in patients with mild to moderate renal impairment (CrCl 10ml/min or greater).

Dose Range: **Adult:** Hypertension, not for initial therapy, doses range from amlodipine 5mg/valsartan 160mg to amlodipine 10mg/valsartan 320mg once daily, with dose titration occurring every 3 to 4 weeks if necessary; Amlodipine 10mg/valsartan 320mg maximum dose. **Pediatric:** safety and efficacy in pediatric patients have not been established.

Preparations:

Tablet 5mg A/80mg V

*Exforge (NVS/COL); 1.3457 per Tab. (30)

Tablet 5mg A/160mg V

*Exforge (NVS/COL); 1.3457 per Tab. (30)

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))*

Tablet 10mg A/160mg V

***Exforge (NVS/COL); 1.3457 per Tab. (30)**

Tablet 10mg A/320mg V

***Exforge (NVS/COL); 1.3457 per Tab. (30)**

Tablet 5mg A/320mg V

Exforge (NVS/COL); 1.3457 per Tab. (30)*4. BAMBUTEROL (B)***Therapeutic Category:* Prodrug of terbutaline.*Indications:* Bronchospasm, Asthma.*Caution/Side Effects:* Tremor, palpitations, headache. *c.f. prescribing in liver and renal disease p. 11; 23.**Dose Range:* 1-3 tablets once daily in the evening.*Preparations:*

Tablet, 10mg

*Consult the BDS for Supplies.***5. BENFLUOREX***Therapeutic Category:* Fenfluramine derivative*Indications:* Hyperlipidaemias of the types IIa, IIb and IV in patients who have not responded adequately to diet and other appropriate measures. Adjunct in the management of non-insulin dependent diabetes mellitus.*Caution/Side Effects:* G.I. upset, dizziness, drowsiness, diarrhoea.*Dose Range: Adult:* One tablet three times daily after meals. Patient should be started on 1 tablet daily with dinner for 1st week, then two daily for 2nd week with lunch and dinner and 1 three times daily with meals thereafter to reduce G.I. upset.

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Preparations:

Tablet, 150mg

Consult the BDS for Supplies. (No Offers to Supply)

Tablet, 300mg

***Medi axial FP (SER/STO); 0.3767 per Tab. (90)**

6. BETAMETHASONE/GENTAMYCIN/CLOTRIMAZOLE

Indications: Mild inflammatory dermatoses with fungal infection.

Caution/Side Effects: See Betamethasone/Gentamycin.

Dose Range: See Betamethasone/Gentamycin.

Preparation:

Cream, Betamethasone/Gentamycin/Clotrimazole

Consult the BDS for Supplies. (No Offers to Supply)

7. BEZAFIBRATE

Therapeutic Category: A fibric acid hypolipidemic agent.

Indications: Effective in normalizing lipid and lipoprotein abnormalities in patients with types II and IV hyper-lipoproteinemia.

Caution/Side Effects: Nausea, vomiting, abdominal pain, headache, dizziness, insomnia, reduced libido, changes in hepatic function tests and cutaneous reactions. May induce gallstone formation. **There is an increased incidence of myopathy (Rhabdomyolysis) if the statins are given with a fibrate. See protocol pg. x section 5.**

Dose Range: **Adult:** 200mg orally three times daily or 400mg once daily, with or after food.

Preparations:

Tablet, 200mg

Consult the BDS for Supplies. (No Offers to Supply).

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***8. BISOPROLOL/HYDROCHLORTHIAZIDE (B)***Therapeutic Category:* Beta-Adrenergic Blocker, Cardioselective, thiazide diuretic.*Indications:* Hypertension.*Caution/Side Effects:* Hypoglycemia, rash, acne, skin irritation, pruritus, diaphoresis, nausea, vomiting, constipation, diarrhea, muscle pain.*Dose Range:* **Adult:** Initially one tablet (2.5/6.25) once daily to maximum 20/12.5mg once daily. **Pediatric 6-17 years:** 2.5/6.25 - 10/6.25mg once daily.*Preparations:*

Tablet, 2.5mg B/HCTZ 6.25mg

***Bisoprolol (DNB/LAS); 0.2694 per Tab. (30)**

Tablet, 5mg B/HCTZ 6.25mg

***Bisoprolol (DNB/LAS); 0.3383 per Tab. (30)**

Tablet, 10mg B/HCTZ 6.25mg

Bisoprolol (DNB/LAS); 0.5076 per Tab. (30)*9. BUMETANIDE (B)***Therapeutic Category:* Loop diuretic.*Indications:* To treat edema associated with congestive heart failure and renal or liver disease. It is also used in the treatment of hypertension.*Caution/Side Effects:* Electrolyte abnormalities such as hypokalemia, hyponatremia and hyperuricemia may occur with therapy. Muscle cramps and arthralgias have also been reported.*Dose Range:* **Adult:** 0.5-2mg/day as a single dose to a maximum of 10mg/day.*Preparations:*

Injection, 0.5mg/ml

***Bumetanide (BEV/LAS); 3.4990 per Amp.**

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Tablet, 1mg

Consult the BDS for Supplies. (No Offers to Supply)

10. CANDESARTAN (B)

Therapeutic Category: Angiotensin II receptor antagonist.

Indications: Treatment of hypertension.

Caution/Side Effects: Dizziness and headache, upper respiratory tract infection. Back pain. Foetal and neonatal toxicity has been reported in babies born to women treated with candesartan during pregnancy. *See protocol pg. xii section 6.*

Dose Range: Initial dose as monotherapy is 16mg once daily; effective dose range is 8-32mg in one or two divided doses. No dose adjustments are needed for renal impairment, mild hepatic dysfunction, age, or gender.

Preparations:

Tablet, 8mg

*Atacand (AZN/BRY); 1.1564 per Tab. (30) 28's

*Atacand (AZN/BRY); 1.1564 per Tab. (30) 100's

Tablet, 16mg

*Atacand (AZN/BRY); 1.1564 per Tab. (30) 28's

*Atacand (AZN/BRY); 1.1564 per Tab. (30) 100's

Tablet, 32mg

*Atacand (AZN/BRY); 1.6139 per Tab. (30)

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***11. CANDESARTAN/HYDROCHLOROTHIAZIDE (B)**

Therapeutic Category: Angiotensin II receptor antagonist; hydrochlorothiazide is a diuretic.

Indications: Mild-to-severe hypertension in patients responding poorly to diuretic or other monotherapy. Its main use is in patients who cannot tolerate ACE inhibitors.

Caution/Side Effects: Respiratory tract infection, back pain, dizziness, and flu-like symptoms. Rises in serum creatinine and liver enzymes have occurred in some patients. *See protocol pg. xii section 6.*

Dose Range: In hypertension, the usual dose of the combination product is 16 or 32mg candesartan plus 12.5mg hydrochlorothiazide once daily.

Preparations:

Tablet, 16mg C/12.5mg H

***Atacand Plus (AZN/BRY); 1.1475 per Tab. (30)**

Tablet, 32mg C/12.5mg H

***Atacand Plus (AZN/BRY); 1.6061 per Tab. (30)**

12. CARBENICILLIN SODIUM

Therapeutic Category: Antibiotic, synthetic penicillin.

Indications: Infections with *Pseudomonas aeruginosa* and *Proteus* sp. and *Escherichia coli*.

Caution/Side Effects: Hematologic effects, coagulation defects, seizures, urticaria, fever, joint pains, angioneurotic oedema, diarrhoea and anaphylactic shock, as for Penicillin G. History of allergy, penicillin hypersensitivity. Note high sodium content of high dose regime. **Take tablets on an empty stomach with a large glass of water.** *c.f. prescribing in renal disease p. 25.*

Dose Range: 382-764mg 4 times daily.

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Preparations:

Tablet, 382mg

Consult the BDS for supplies. (No Offers to Supply).

13. CETIRIZINE

Therapeutic Category: A long acting selective peripheral H₁- receptor antagonist of the piperazine group with minimal anti-cholinergic activity and low sedating properties.

Indications: Seasonal allergic rhinitis, perennial allergic rhinitis, chronic idiopathic urticaria.

Caution/Side Effects: **May cause drowsiness**, fatigue, dry mouth, headache, sore throat and stomach ache.

Dose Range: Adult and Pediatrics over 6 yrs: 5-10mg once daily or in divided doses. **Pediatric: 2-6 yrs** 5mg daily or 2.5mg twice daily. 6 to 23 mths 2.5mg once daily. *See protocol pg. xiv section 12.*

Preparations:

Tablet, 10mg

***Apo-Cetirizine (APO/COL); 0.0702 per Tab. (14)**

***Cetirizine (CIP/LAS); 0.0538 per Tab. (14)**

Syrup, 1mg/ml

***Cetirizine (CIP/LAS); 0.0197 per ml (30mls)**

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***14. CERTOPARIN**

Therapeutic Category: Low-molecular-weight heparin.

Indications: Prophylaxis of peri- and postoperative venous thromboembolism.

Caution/Side Effects: Certoparin is contraindicated in patients with major bleeding disorders, bleeding ulcers of the stomach or intestine, severe hypertension, subacute bacterial endocarditis, severe renal or hepatic dysfunction, or a previous history of hypersensitivity to heparin.

Dose Range: 3,000 IU subcutaneously once daily, with the first dose administered 1-2 hours prior to surgery, and once daily thereafter for 7-10 days or until the patient is mobile.

Preparations:

Inj. 3,000 Units per vial

Consult the BDS for Supplies. (No Offers to Supply).

15. CHLORPHENIRAMINE-PSEUDOEPHEDRINE

Indications: See notes under Chlorpheniramine Maleate.

Caution/Side Effects: See notes under Chlorpheniramine Maleate.

Dose Range: One to two teaspoonsful three times a day or one tablet three times daily. *See protocol pg. xiv section 12.*

Preparations:

Syrup, 0.4mg/mg C/6mg/ml P per ml; 2 litres

***Histal DC (CAR/COL); 0.0140 per ml. (100)**

Tablet,

***Histal DC (CAR/COL); 0.3151 per Tab. (42)**

SCHEDULE – *Cont'd*

(*Paragraph 3*)

PART I – *Cont'd*

(*Paragraph 3(a)*)

16. CHLORPROPAMIDE (B)

Therapeutic Category: Sulfonylurea.

Indications: Diabetes mellitus, mature onset, without ketosis; when dietary control fails. It is partly excreted in the kidney and partly metabolised (slowly) in the liver, and has a long half-life (24-48 hours). It therefore accumulates in the elderly and in renal failure, tolbutamide would be a safer choice in such patients.

Caution/Side Effects: Nausea, diarrhea, vomiting, pruritus. Prolonged hypoglycaemia may occur, especially in the elderly and with renal impairment. Chlorpropamide and tolbutamide may cause facial flushing after drinking alcohol. *c.f. prescribing in liver and renal disease p. 12; 26.*

Dose Range: 125-500mg daily with breakfast. *See protocol pg. xiii section 9.*

Preparations:

Tablet, 250mg

***Prodiabet (CAM/SBI); 0.0614 per Tab.**

17. COLESTIPOL

Therapeutic Category: Basic anion exchange resin.

Indications: Indicated in the treatment of primary type IIa hyperlipoproteinemia, and has also been utilized in digitalis overdose and antibiotic associated pseudomembranous colitis.

Caution/Side Effects: Can interfere with normal fat absorption and prevent absorption of fat soluble vitamins; constipation is the most frequent adverse effect.

Dose Range: Adult: The recommended dosage is 2-16g/day administered as a single or divided doses. The initial dosage is 2g once or twice daily.

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))**Preparations:*

Tablet, 1g

Consult the BDS for Supplies. (No Offers to Supply)

Granules

*Consult the BDS for Supplies. (No Offers to Supply)***18. DESONIDE***Indications:* A low potency corticosteroid in topical treatment of various skin disorders.*Caution/Side Effects:* See under Betamethasone Valerate.*Dose Range:* Apply sparingly. Rub in lightly twice daily. *See protocol pg. x section 4.**Preparations:*

Ointment, 0.05%; 15g tube.

Consult the BDS for Supplies. (No Offers to Supply)

Cream, 0.05%; 15g tube

*Consult the BDS for Supplies. (No Offers to Supply)***19. DIFLUCORTOLONE-ISOCONAZOLE-NEOMYCIN***Indications:* Inflammatory dermatoses with fungal and bacterial infections.*Caution/Side Effects:* See under Betamethasone Valerate.*Dose Range:* Initially apply twice to three times daily then reduce to once daily. *See protocol pg. x section 4.*

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Preparations:

Cream, 0.1% D/1% I/0.5% N; 10g Tube

***Schederma (BSP/COL); 7.2400 per Tube. (2 Tubes)**

***Schederma (BSP/LAS); 7.2400 per Tube. (2 Tubes)**

20. DIFLUNISAL

Therapeutic Category: Nonsteroidal anti-inflammatory drug.

Indications: Mild to moderate pain, especially that associated with osteoarthritis and rheumatoid arthritis.

Caution/Side Effects: Patients sensitive to aspirin. Swallow tablet whole, do not chew or crush. May cause G.I. upset. **Not recommended in children under 12.** *c.f. prescribing in liver and renal disease p. 13; 28.*

Dose Range: **Pain:** 250-500 mg every 8-12 hrs. **Arthritis:** 500-1000mg twice daily, *See protocol pg. ix section 3.*

Preparations:

Tablet, 500mg

Consult the BDS for Supplies. (No Offers to Supply)

21. DIHYDROCODEINE(N)

Therapeutic Category: Narcotic Analgesic.

Indications: Moderate to severe pain (more potent than codeine).

Caution/Side Effects: As for codeine. Use with caution in patients with respiratory disease. *c.f. prescribing in liver and renal disease p. 13; 28.*

Dose Range: 30-60mg every 4-6 hours when necessary. **Take after meals.** *See protocol pg. ix item vii.*

Preparations:

Tablet, 30mg

Consult the BDS for Supplies. (No Offers to Supply)

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***22. DIOSMIN-HESPERIDIN**

Indications: Treatment of organic and functional chronic venous insufficiency of the lower limbs.

Caution/Side Effects: G.I. upset.

Dose Range: **Chronic Venous Insufficiency:** 2 tablets daily. **Hemorrhoids: Acute Bleeding:** 6 tablets daily for 4 days, followed by 4 tablets daily for 3 days. **Recurrent attacks:** 2 tablets daily for 3 months. *See protocol pg. xv section 15.*

Preparations:

Diosmin 500mg/Hesperidin 50mg

***Daflon (SER/STO); 0.5283 per Tab. (60)**

***Diosmin-Hesperidin (CIP/BKL); 0.3597 per Tab. (60)**

23. DIPYRIDAMOLE

Therapeutic Category: Antiplatelet Agent.

Indications: Angina pectoris and transient ischaemic attacks. Decreasing pre-load in patients with chronic intractable heart failure.

Caution/Side Effects: Value of drug has not yet been clearly established. Hypotension, dizziness, headache.

Dose Range: 75mg 3 times daily.

Preparations:

Tablet, SC, 25mg

***Apo-Dipyridamole (APO/COL); 0.0606 per Tab. (90)**

Tablet, SC, 50mg

***Apo-Dipyridamole (APO/COL); 0.0727 per Tab. (90)**

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Tablet, FC, 75mg

***Apo-Dipyridamole (APO/COL); 0.0848 per Tab. (90)**

24. ECONAZOLE

Therapeutic Category: Imidazole antimycotic agent.

Indications: For yeast infections; candidiasis.

Caution/Side effects: Burning, stinging and erythema.

Dose Range: Insert 1 ovule into the vagina at night for 3 nights. Continue use during menstrual period.

Preparations:

Ovule, Vaginal, 150mg; 3's

***Gyno-Pevaryl (JAC/STO); 7.0500 per Pack. (1 Pack)**

25. ENALAPRIL/HYDROCHLORTHIAZIDE (B)

Therapeutic Category: ACE Inhibitor combined with a thiazide diuretic.

Indications: Hypertension, congestive heart failure.

Caution/Side Effects: Impotence, gastrointestinal symptoms, dizziness, fatigue, cough, muscle cramps and orthostatic hypertension. *See notes on page 197.*

Dose Range: One tablet daily. **The fixed dose combination is not indicated for initial therapy and is not suitable for titration.** *See protocol pg. xii section 6.*

Preparations:

Tablet, 20mg E/12.5mg H

***Enalapril/HCTZ (DNB/LAS); 0.3219 per Tab. (30)**

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***26. FELODIPINE (B)**

Therapeutic Category: Dihydropyridine Calcium Channel Blocker. (*see further notes on p. 198*).

Indications: Hypertension.

Caution/Side Effects: Titrate doses in patients with impaired renal and hepatic function and CHF. Peripheral edema, skin rash, dizziness, gingival hyperplasia and flushing. **Do not crush tablet.** Avoid grapefruit juice as this may cause severe hypotension, myocardial ischaemic and increased vasodilator effects.

Dose Range: 5-10mg once daily. In patients over 65 years begin at 2.5mg daily. **A 7.5MG DOSE CAN BE OBTAINED FROM THE 2.5MG AND 5MG TABLETS.**

Preparations:

Tablet, 2.5mg

***Felodipine (CIP/BKL); 0.3167 per Tab. (30)**

Tablet, 5mg

***Felodipine (CIP/BKL); 0.2413 per Tab. (30)**

Capsule, 10mg

***Felodipine XL (TLM/COL); 0.2404 per Cap.**

27. FENOFIBRATE

Indications: Same as Gemfibrozil.

Caution/Side Effects: Renal and hepatic impairment; hypo-albuminaemia; gall bladder disease; pregnancy; nausea; G.I. upset, pruritis; urticaria. *c.f. prescribing in liver and renal disease p. 13; 29. See protocol pg. x section 5.*

Dose Range: **Adult:** One capsule daily with a meal.

SCHEDULE – Cont'd

(Paragraph 3)

PART I – Cont'd

(Paragraph 3(a))

Preparations:

Capsule, 100mg

***Apo-Fenofibrate (APO/COL); 0.1636 per Cap. (90)**

Capsule, 200mg

Consult the BDS for Supplies. (No Offers to Supply)

Capsule, 300mg

Consult the BDS for Supplies. (No Offers to Supply)

28. FENOTEROLHYDROBROMIDE(B)

Therapeutic Category: B₂ agonist with similar potency to albuterol and terbutaline.

Indications: For the symptomatic relief of bronchospasm in bronchial asthma and bronchitis.

Caution/Side Effects: Because of longer duration of action when compared to other beta 2 agonists, dosage should be carefully monitored. Tachycardia, palpitations, tremor, nervousness.

Dose Range: Adult: 200-400 micrograms (1-2 puffs) 3 times daily. *See protocol pg. xiv section 14.*

Preparations:

Inhaler, 100mcg per metered dose; 200 doses

***Berotec N (BOE/STO); 13.4600 per Inhaler. (1 Inhaler)**

Syrup, 0.5%; 125ml

***Berotec (BOE/STO); 0.0861 per ml. (125mls)**

Respirator Solution, 0.1%; 20ml bottle

Consult the BDS for Supplies. (No Offers to Supply)

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***29. FLUOCINOLONE ACETONIDE***Indications:* For relief of inflammation and itching.*Caution/Side Effects:* See Betamethasone Valerate*Dose Range:* Apply 2-3 times daily. **Use sparingly.** *See protocol pg. x section 4.**Preparations:*

Cream, 0.025%; 15g Tube

***Fluocinolone (ASL/PHA); 1.8000 per Tube. (2 Tubes)**

Ointment, 0.025%; 15g Tube

*Consult the BDS for Supplies. (No Offers to Supply)***30. FLUOCINOLONE/CLOTRIMAZOLE***Indications:* Inflammatory dermatoses.*Caution/Side Effects:* Apply sparingly.*Dose Range:* Apply twice daily.*Preparations:*

Ointment, 0.3%F/1%C

***Flucort (GLP/ARM); 2.8300 per Tube. (2 Tubes)**

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

31. FLUOCINOLONE/NEOMYCIN

Therapeutic Category: Topical corticosteroid with antibiotic.

Indications: Inflammatory dermatoses requiring antibiotics.

Caution/Side Effects: Apply sparingly.

Dose Range: Apply twice daily. *See protocol pg. x section 4.*

Preparations:

Cream, 0.025% F/0.5% N

Consult the BDS for Supplies. (No Offers to Supply)

32. FLURBIPROFEN

Therapeutic Category: Nonsteroidal anti-inflammatory drug.

Indications: Pain and inflammation in rheumatic and musculoskeletal disorders.
Dental pain.

Caution/Side Effects: G.I. upset, headache, dizziness, allergic disorders (as for aspirin) but less frequent. May administer with meals or milk if G.I. upset occurs.
c.f. prescribing in liver and renal disease p. 13; 29.

Dose Range: Dental Pain: 50-100mg once daily. Arthritis: 200-300mg daily. *See protocol pg. ix section 3.*

Preparations:

Tablet, 50mg

Consult the BDS for Supplies. (No Offers to Supply)

Tablet, 100mg

Consult the BDS for Supplies. (No Offers to Supply)

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***33. FLUVASTATIN**

Therapeutic Category: HMG-CoA reductase inhibitor.

Indications: Primary hypercholesterolaemia in patients with cholesterol concentrations of 6.5mmol/L or greater and resistant to dietary control.

Caution/Side Effects: Gastrointestinal upset, headache, dyspepsia, diarrhoea, abdominal pain and nausea. Caution in liver disease and pregnancy. *c.f. prescribing in liver and renal disease p. 13; 29.* See Lovastatin. *See protocol pg. x section 5.*

Dose Range: **Adult:** 20-40mg daily with evening meal. *See protocol pg. x section 5.*

Preparations:

Capsule, 20mg

***Fluvastatin (CIP/BKL); 0.7990 per Cap. (30)**

Capsule, 40mg

***Fluvastatin (CIP/BKL); 1.0390 per Cap. (30)**

34. FOSINOPRIL (B)

Therapeutic Category: ACE Inhibitor.

Indications: Mild to moderate hypertension. Adjunct in CHF.

Caution/Side Effects: Use with caution in severe renal or hepatic impairment. Headache, fatigue, cough, pharyngitis, diarrhoea, dizziness, rash, hyperkalemia. See notes on page 200. *c.f. prescribing in renal disease p. 29.*

Dose Range: **Adult:** 5-40mg once daily. The 5mg is obtained by breaking the 10mg tablet in half. *See protocol pg. xii section 6.*

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Preparations:

Tablet, 10mg scored

***Apo-Fosinopril (APO/COL); 0.4360 per Tab.**

Tablet, 20mg

***Fosinopril (RIM/PHA); 0.4139 per Tab.**

35. FOSINOPRIL/HYDROCHLORTHIAZIDE (B)

Therapeutic Category: ACE Inhibitor combined with a thiazide diuretic.

Indications: Mild to moderate hypertension. Adjunct in CHF.

Caution/Side Effects: Use with caution in renal or hepatic impairment. Headache, fatigue, cough, pharyngitis, diarrhoea, rash, hyperkalemia. **The fixed dose combination is not indicated for initial therapy and is not suitable for titration.** See notes on page 195. *c.f. prescribing in renal disease p. 29. See protocol pg. xii section 6.*

Dose Range: Adult: 5–40mg once daily. *See protocol pg. xii section 6.*

Preparations:

Tablet, 10mg F/12.5mg H

Consult the BDS for Supplies. (No Offers to Supply)

Tablet, 20mg F/12.5mg H

Consult the BDS for Supplies. (No Offers to Supply)

36. GLIPIZIDE (B)

Therapeutic Category: Second generation sulfonylurea.

Indications: Treatment of diabetes mellitus.

Caution/Side Effects: Hypoglycemia, nausea, diarrhoea, abdominal pain, rash, pruritus. Concurrent administration of food and glipizide may result in delayed insulin release. **Take as a single dose before breakfast.** *c.f. prescribing in liver and renal disease p. 14; 30.*

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))*

Dose Range: 5-20mg daily. *See protocol pg. xiii section 9.*

Preparations:

Tablet, 5mg

***Glipizide XL (DNB/LAS); 0.3883 per Tab. (60)**

***Glucotrol XL (PFI/SBI); 0.5232 per Tab. (60)**

Tablet, 10mg

***Glipizide XL (DNBBK/L); 0.7613 per Tab. (60)**

***Glucotrol XL (PFI/SBI); 1.0122 per Tab. (60)**

37. GLYBURIDE (B)

Therapeutic Category: Second generation sulfonylurea.

Indications: Treatment of type II diabetes mellitus. A second generation sulfonylurea. **Glyburide is the micronised form of Glibenclamide and prescriptions for both will not be honoured.**

Caution/Side Effects: Hypoglycemia, G.I. upset and allergic skin reactions.

Dose Range: 1.5-12mg daily. *See protocol pg. xiii section 9.*

Preparations:

Tablet, 3mg, Scored

***Glyburide Micro (DNB/LAS); 0.4823 per Tab. (60)**

***Glynase (PFI/STO); 0.9325 per Tab. (60)**

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Tablet, 6mg, Scored

***Glyburide Micro (DNB/LAS); 0.7221 per Tab. (60)**

***Glynase (PFI/STO); 1.5259 per Tab. (60)**

38. HALOTHANE

Indications: General anaesthetic. See also p. 253.

Caution/Side Effects: Hypotension, decreased heart rate, arrhythmias and respiratory depression.

Dose Range: Dosage varies with requirements between 0.5-3% in oxygen or nitrous oxide/oxygen.

Preparations:

250ml bottle

Consult the BDS for Supplies.

39. HEXAMINE HIPPURATE

Indications: Cystitis. It is of little use for tissue infections, e.g. pyelonephritis, because of low tissue levels, but is valuable in cystitis, and particularly for chronic and recurrent infection. *c.f. prescribing in renal disease p. 30.*

Dose Range: **Adult:** 1g every 12 hours. **Pediatric:** 500mg every 12 hours.

Preparations:

Tablet, 1g

Consult the BDS for Supplies. (No Offers to Supply)

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***40. HYDROCORTISONE/MICONAZOLE***Indications:* See under Hydrocortisone/Econazole.*Caution/Side Effects:* See under Hydrocortisone/Econazole.*Dose Range:* Apply 1-2 times daily. *See protocol pg. x section 4.**Preparations:*

Cream, Miconazole 2%/Hydrocortisone 1%; 30g tube

*Consult the BDS for Supplies. (No Offers to Supply)***41. INDOMETHACIN***Therapeutic Category:* Nonsteroidal anti-inflammatory drug.*Indications:* Pain and inflammation in rheumatic/musculo-skeletal disorders e.g. gout.*Caution/Side Effects:* G.I. upset, frontal headaches, dizziness, abdominal pain, constipation, diarrhea. Contraindicated in peptic ulcers, salicylate hyper-sensitivity. *c.f. prescribing in liver and renal disease p. 14; 31.**Dose Range:* 25-50mg 2-4 times daily, or 75mg as the sustained release capsule once daily. Take with milk, antacids or after meals for chronic use. *See protocol pg. ix section 3.**Preparations:*

Tablet, 25mg

***Indomethacin (STP/COL); 0.0188 per Tab. (90)**

Tablet/Capsule, sustained release, 75mg

***Rheumacin SR (PPL/COL); 0.3848 per Cap. (14)**

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

42. IODOCHLORHYDROXYQUINOLONE WITH HYDROCORTISONE ACETATE

Indications: Inflammatory dermatoses.

Caution/Side Effects: **Contains topical corticosteroids.**

Dose Range: Apply twice daily. *See protocol pg. x section 4.*

Preparations:

Ointment, Iodochlorhydroxyquinolone 3%/Hydrocortisone 1%; 15g tube

***Carloquin H (CAR/COL); 8.9900 per Tube. (2 Tubes)**

43. IRBESARTAN (B)

Therapeutic Category: Angiotensin II Receptor Antagonist.

Indications: Diabetes mellitus, hypertension, kidney disease.

Caution/Side Effects: Pregnancy, angioedema (face, lips, throat), Rhabdomyolysis.

Dose Range: **Adult: Diabetes mellitus - Hypertension - Kidney disease:**
Maintenance dose: 300mg orally once daily. **Hypertension:** 150mg orally once daily. **Maximum dose:** 300mg once daily. **Pediatric: Hypertension: 6-12 years:** 75mg orally once daily, may titrate to 150mg once daily based on response. **13-16 years:** 150mg orally once daily, may titrate to 300mg once daily based on response. **Maximum dose:** 300mg daily. *See protocol pg. xii section 6.*

Preparations:

Tablet. 150mg

***Aprovel (SFI/COL); 1.1300 per Tab. (30)**

Tablet, 300mg

***Aprovel (SFI/COL); 1.1300 per Tab. (30)**

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***44. IRBESARTAN/HYDROCHLOROTHIAZIDE (B)***Therapeutic Category:* Angiotensin II Receptor Antagonist/Thiazide.*Indications:* Hypertension, not initial therapy.*Caution/Side Effects:* Angioedema (face, lips, throat), Rhabdomyolysis, nausea, vomiting, abdominal pain, flu-like symptoms. Do not use in pregnancy. Risk in breast feeding is unknown.*Dose Range: Adult: Hypertension:* Initial 150mg irbesartan/12.5mg HCTZ once daily. Allow 2-4 weeks to achieve maximal antihypertensive effect. *Maintenance:* 300mg irbesartan/12.5mg HCTZ. *See protocol pg. xii section 6.**Preparations:*

Tablet, 150mg I/12.5mg H

***Co-Aprovel (SFA/COL); 1.1300 per Tab. (30)**

Tablet, 300mg I/12.5mg H

Co-Aprovel (SFA/COL); 1.1300 per Tab. (30)*45. ISOCONAZOLE***Therapeutic Category:* Imidazole antifungal agent.*Indications:* Vaginal candidiasis.*Caution/Side Effects:* Burning, itching.*Dose Range:* One applicator full into the vagina at night for 7 consecutive nights or one single-dose vaginal ovule. Continue use during menstrual period.*Preparations:*

Vaginal Cream, 1%; 40g Tube

Gyno-Travogen (BSP/BKL); 9.6600 per Tube. (1 Tube)**Gyno-Travogen (BSP/COL); 9.6600 per Tube. (1 Tube)*****Gyno-Travogen (BSP/LAS); 9.6600 per Tube. (1 Tube)**

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Vaginal Ovule, 600mg

*Gyno-Travogen (BSP/BKL); 8.3700 per Pack. (1 Pack)

*Gyno-Travogen (BSP/COL); 8.3700 per Pack. (1 Pack)

*Gyno-Travogen (BSP/LAS); 8.3700 per Pack. (1 Pack)

46. ISRADIPINE (B)

Therapeutic Category: Dihydropyridine Calcium Channel Antagonist (see further notes on p. 196.)

Indications: Treatment of mild to moderate hypertension.

Caution/Side Effects: Reduce dosage in hepatic or renal impairment and the elderly; pregnancy. Headache, flushing, rashes, peripheral edema, gingival hyperplasia and dizziness. Avoid with grapefruit juice. *c.f. prescribing in liver p. 14.*

Dose Range: 2.5mg twice daily or 5-10mg sustained release once daily. Maximum: 20mg/day.

Preparations:

Tablet, 5mg

*Dynacirc SRO (NVS/COL); 0.9517 per Tab. (30)

47. KETOPROFEN

Therapeutic Category: Nonsteroidal anti-inflammatory drug.

Indications: Pain and mild inflammation in rheumatic and other musculo-skeletal disorders.

Caution/Side Effects: G.I. upset. *c.f. prescribing in liver and renal disease p. 14; 31.*

Dose Range: 200mg daily as a single dose with food milk or antacids. *See protocol pg. ix section 3.*

SCHEDULE – Cont'd

(Paragraph 3)

PART I – Cont'd

(Paragraph 3(a))

Preparation:

Tablet, 200mg

Apo-Keto Mod Rel (APO/COL); 0.3149 per Tab. (14)*48. KETOROLACTROMETAMOL***Therapeutic Category:* Nonsteroidal anti-inflammatory drug.*Indications:* Short term management of moderate to severe acute postoperative pain.*Caution/Side Effects:* G.I bleeding especially in the elderly. Fluid retention, anaphylaxis, nausea, headache. Monitor in renal or hepatic impairment. *c.f. prescribing in liver disease p. 14.**Dose Range:* **Oral:** 10-30mg every 4-6 hours (every 2 hours in initial post-operative period). Maximum of 90mg daily (60mg in the elderly and patients weighing less than 50kg). **Injection:** 60mg IM stat dose or 30mg IM every 6 hrs to a maximum of 120mg/day.*Preparation:*

Inj. 15mg/ml; 1ml vial.

***Ketorolac (HOS/PHA); 1.9120 per Amp.**

Inj. 30mg/ml; 2ml vial.

Ketorolac (CIP/LAS); 6.0550 per vial.*49. LISINAPRIL/HYDROCHLOROTHIAZIDE (B)***Therapeutic Category:* ACE Inhibitor in combination with a thiazide diuretic.*Indication:* Hypertension in patients for whom combination therapy is appropriate.*Caution/Side Effects:* Dizziness, headache, fatigue, cough, nausea, muscle cramps, hypotension. **The fixed dose combination is not indicated for initial therapy and is not suitable for titration.** See notes on page 195. *c.f. prescribing in renal disease p. 31.*

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Dose Range: Adult: One tablet once daily. *See protocol pg. xii section 6.*

Preparation:

Tablet, 10mg L/12.5mg H

***Lisinopril (RBX/BKL); 0.2519 per Tab. (30)**

Tablet, 20mg L/12.5mg H

***Apo-Lisinopril (APO/COL); 0.4118 per Tab. (30)**

50. LORATADINE/PSEUDOEPHEDRINE

Therapeutic Category: Antihistamine/Decongestant combination.

Indications: Seasonal allergic rhinitis.

Caution/Side Effects: Narrow-angle glaucoma, severe coronary artery disease, severe hypertension, urinary retention.

Dose Range: Seasonal allergic rhinitis: 1 tablet orally twice daily. **Pediatric:** 1 tablet twice daily. Safety and efficacy not established in children less than age 12. *See protocol pg. xiv section 12.*

Preparations:

Tablet, 5mg L/120mg P

***Loratadine/Pseudoephedrine (CIP/BKL); 0.7240 per Tab. (28)**

51. LOSARTAN/HYDROCHLOROTHIAZIDE (B)

Therapeutic Category: Antihypertensive agents losartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a benzothiazine diuretic) are available in a fixed-dose combination.

Indications: The combination of losartan/hydrochlorothiazide is indicated for the treatment of hypertension (but not as initial therapy).

Caution/Side Effects: Dizziness, back pain, upper respiratory infection and cough. The combination should not be used during the second and third trimesters of pregnancy.

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))*

Dose Range: 50/12.5mg once daily. If after 3 weeks blood pressure remains elevated then the dosage may be increased to losartan/hydrochlorothiazide 100/25mg once daily. *See protocol pg. xii section 6.*

Preparations:

Tablet, 50mg L/12.5mg H

***Nusar H (EMC/COL); 0.0510 per Tab.**

Tablet, 100mg L/25mg H

***Hyzaar (MSD/STO); 1.1840 per Tab.**

Tablet 100mg L/12.5mg H

***Hyzaar (MSD/STO); 1.1840 per Tab. (30)**

52. LOVASTATIN

Therapeutic Category: HMG-CoA reductase inhibitor.

Indications: Treatment of primary high cholesterol, arterosclerosis, prevention of coronary artery disease and familial hypercholesterolemia.

Caution/Side Effects: Flatulence, headache, myalgia and constipation. Do not use with grapefruit juice, Gemfibrozil, Ketoconazole, Fenofibrate or Warfarin. *See protocol pg. x section 5.*

Dose Range: Adult: 20mg daily with evening meal. Maximum of 80mg daily in single or two divided doses.

Preparations:

Tablet, 20mg

Consult the BDS for Supplies. (No Offers to Supply).

Tablet, 40mg

Consult the BDS for Supplies. (No Offers to Supply).

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

53. MEDROGESTONE

Indications: Treatment of menstrual disorders and as the progestogen in menopausal hormone replacement therapy.

Caution/Side Effects: Fluid retention, menstrual disorders. Use with caution in conditions which worsen fluid retention. *c.f. prescribing in liver disease p. 15.*

Dose Range: 5-10mg by mouth, generally in a cyclical regimen

Preparations:

Tablet, 5mg

Consult the BDS for Supplies. (No Offers to Supply)

54. MEFENAMIC ACID

Therapeutic Category: Nonsteroidal anti-inflammatory drug.

Indications: Dysmenorrhoea; mild to moderate pain in rheumatoid arthritis; surgical pain.

Caution/Side Effects: Drowsiness, G.I. upset, agranulocytosis hemolytic anemia. **Not recommended in children under 14 years. Take with food.** *c.f. prescribing in liver and renal disease p. 15; 32.*

Dose Range: Adult: Hemolytic anemia and Pediatric Over 14 years 500mg initially, followed by 250mg every 6 hours as needed with food. *See protocol pg. ix section 3.*

Preparations:

Tablet, 250mg

***Apo-Mefenamic Acid (APO/COL); 0.1817 per Tab. (42)**

Tablet/Capsule, 500mg

***Mefemic (CAM/SBI); 0.0557 per Tab. (42)**

Paed. Susp. 10mg/ml; 100ml bottle

Consult the BDS for Supplies. (No Offers to Supply)

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***55. MELOXICAM**

Therapeutic Category: A nonsteroidal anti-inflammatory agent with selectivity for cyclooxygenase-2.

Indications: Effective in the treatment of rheumatoid arthritis, osteoarthritis

Caution/Side Effects: Headache, nausea, diarrhoea, edema, dizziness, upper respiratory tract infection, rash. Cross sensitivity may occur with other NSAIDs.
Take with food.

Dose Range: For the treatment of osteoarthritis, the recommended starting and maintenance dose is 7.5mg once daily. *See protocol pg. ix section 3.*

Preparation:

Tablet, 7.5mg

***Apo-Meloxicam (APO/COL); 0.0727 per Tab. (14)**

Tablet, 15mg

***Apo-Meloxicam (APO/COL); 0.1453 per Tab. (14)**

***Melorem (REM/SBI); 0.1463 per Tab. (14)**

Inj, 10mg/ml

***Mobic (BOE/STO); 3.3900 per vial.**

56. MEQUITAZINE

Indications: Symptomatic relief of allergic conditions such as, urticaria, rhinitis and conjunctivitis.

Caution/Side Effects: May cause drowsiness. Warn patients re ingesting alcohol, driving and operating heavy machinery. Dry mouth.

SCHEDULE - *Cont'd*

(Paragraph 3)

PART I - *Cont'd*

(Paragraph 3(a))

Dose Range: Adult: 1 tablet twice daily; may be reduced to 1 daily after 5 days.

Pediatric: 1.25mg/5kg body weight daily. *See protocol pg. xiv section 12.*

Preparations:

Tablet, 5mg

***Mequilan (CAR/COL); 0.2989 per Tab. (28)**

Syrup 0.5mg/ml

***Mequilan (CAR/COL); 0.0760 per ml (125mls)**

57. METAMIZOL

Therapeutic Category: Pyrazolone Nonsteroidal anti-inflammatory drug.

Indications: Severe pain associated with smooth muscle spasm where no alternative is available or suitable: Severe or life threatening fever uncontrolled by other measures and for cancer pain. Not to be used in trivial complaints because of risk of serious adverse effects, use is considered justified only in severe pain where no alternative is available or suitable.

Caution/Side Effects: Administration is associated with increased risk of agranulocytosis, anaphylactic shock. Severe cutaneous reactions, bronchospasm.

Dose Range: Tablets: 1-2 tablets daily. **Inj:** 0.5mg-1g. i.m. or i.v. *See protocol pg. viii section 2(v).*

Preparations:

Tablet, 500mg

***Baralgin M (SFA/COL); 0.2153 per Tab. (30)**

Drops, 500mg/ml; 10ml Bottle

***Baralgin M (SFA/COL); 6.3200 per Bottle.**

Inj. 500mg; 2ml Amp.

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))*

***Baralgin M (SFA/COL); 1.8840 per Amp.**

***Diparin (LAF/SBI); 0.4227 per Amp.**

Inj. 500mg; 5ml Amp.

***Baralgin M (SFA/COL); 10.4960 per Amp.**

58. NADOLOL (B)

Therapeutic Category: Beta-Adrenergic Blocker. Non selective.

Indications: Hypertension. Angina pectoris.

Caution/Side Effects: Half-life of about 24 hours. Excreted by the kidney. Accumulates in patients with renal impairment and may cause severe bradycardia. Nausea, diarrhoea, constipation, hypotension, paresthesias, dizziness, sedation and bronchospasm. **WADA Status:** See *Atenolol* p. 230 *c.f. prescribing in renal disease p. 32.*

Dose Range: **Angina:** 40mg daily initially titrate in 40-80mg increments at 3-7 day intervals to a maximum of 240mg. **Arrhythmia:** 60-160mg daily in single or divided doses. **Hypertension:** 40mg daily initially to a maximum of 240-320mg.

Preparations:

Tablet, 80mg

***Apo-Nadol (APO/COL); 0.2422 per Tab. (120)**

59. NALIDIXICACID

Therapeutic Category: Antimicrobial agent.

Indications: Cystitis, especially chronic and recurrent infections. Uncomplicated urinary tract infections.

Caution/Side Effects: **Do not use in 1st trimester of pregnancy.** Infants under 3 months, epilepsy. G.I. upset, nausea, vomiting. Take with full glass of water. Avoid direct sunlight. *c.f. prescribing in liver and renal disease p. 15; 32.*

Dose Range: **Adult:** 1-4g daily in divided doses every 6 hours for 1-2 weeks. For long term therapy use 500mg 4 times daily.

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Preparations:

Tablet, 500mg

Consult the BDS for Supplies. (No Offers to Supply).

60. NATEGLINIDE

Therapeutic Category: Meglitinide hypoglycemic agent.

Indications: Treatment of Type II Diabetes Mellitus alone or in combination with metformin or a thiazolidinedione.

Caution/Side Effects: Hypoglycemia, diarrhea, dyspepsia, nausea, urticaria, upper respiratory infection and flu symptoms. It should not be used in patients with Type I diabetes. *Drug Interactions:* Drugs which increase the risk of hypoglycemia. Gemfibrozil, Guar Gum, Psyllium and St. John's Wort. **Do not use in combination with Sulfonyleureas.**

Dose Range: 60-120mg three times daily. *See protocol pg. xiii section 9.*

Preparations:

Tablet, 120mg

***Starlix (NVS/COL); 0.7849 per Tab. (90) (Public Sector use only).**

61. NIFEDIPINE (B)

Therapeutic Category: Dihydropyridine Calcium Channel Blocker (see further notes on p. 205.)

Indications: Angina pectoris, hypertension. Raynaud's disease.

Caution/Side Effects: See Isradipine. Avoid the use of diuretics. Headache, flushing, dizziness. Use with grapefruit juice may cause severe muscle tenderness and pain. *c.f. prescribing in liver and renal disease p. 15; 33.*

Dose Range: 10mg: 1 capsule 3 times daily.

Preparations:

Capsule/Tablet, 10mg

***Apo-Nifedipine (APO/COL); 0.0848 per Cap. (180)**

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***62. ORPHENADRINE CITRATE**

Indications: Short-term symptomatic relief of muscle spasm.

Caution/Side Effects: Avoid in children, reduce dose in elderly; dizziness, drowsiness, dry mouth, constipation, pruritus.

Dose Range: By intramuscular or slow intravenous injection (over 5 minutes), 60mg repeated after 12 hours if necessary. Oral: 100mg each morning and evening. *See protocol pg. xv section 17.*

Preparations:

Tablet, 100mg

***Norflex (PMA/ARM); 0.3970 per Tab. (14)**

Inj. 30mg/ml; 2ml Amp.

***Orphenadrine (BEV/BKL); 50.4630 per Amp.**

***Orphenadrine (STR/BKL); 50.4630 per Amp.**

63. ORPHENADRINE CITRATE/PARACETAMOL

Indications: See Orphenadrine.

Caution/Side Effects: See Orphenadrine.

Dose Range: 2 tablets three times daily. *See protocol pg. xv section 17.*

Preparations:

Tablet, Orphenadrine 35mg/Paracetamol 450mg

***Norgesic (PMA/ARM); 0.4790 per Tab. (42); 100's**

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

64. PERINDOPRIL (B)

Therapeutic Category: Long acting ACE Inhibitor.

Indications: Essential hypertension. Congestive heart failure, Coronary artery disease.

Caution/Side Effects: Hyperkalemia, cough, headache, dizziness and asthenia. Avoid use of potassium supplements. Do not use in the 2nd and 3rd trimesters of pregnancy. **Drug Interactions:** Avoid use with potassium sparing diuretics. See notes on page 197. *c.f. prescribing in renal disease p. 34.*

Dose Range: 4 to 8mg daily in mild to moderate hypertension. Congestive Heart Failure: 2-4mg daily. **Coronary artery disease:** 4mg once daily for 2 weeks up to 8mg once daily. **Dose reduction for elderly patients.** *See protocol pg. xii section 6.*

Preparations:

Tablet, 4mg; scored

***Perigard (GLP/ARM); 0.5047 per Tab. (45)**

***Perindopril (CIP/BKL); 0.4737 per Tab. (45)**

Tablet, 8mg

***Perindopril (CIP/BKL); 0.9483 per Tab. (45)**

65. PERINDOPRIL/INDAPAMIDE (B)

Therapeutic Category: Combination ACE Inhibitor and diuretic.

Indications: First line treatment of essential arterial hypertension.

Caution/Side Effects: Dry cough, hypotension, salt and water depletion, angioneurotic, oedema of the face, lips, tongue and extremities. **Do not use in patients with hypersensitivity to sulphonamides, hepatic failure, hypokalemia, pregnancy or lactation.** *See protocol pg. xii section 6.*

Dose Range: Adult: One to two tablets daily before breakfast.

SCHEDULE – Cont'd

(Paragraph 3)

PART I – Cont'd

(Paragraph 3(a))

Preparations:

Tablet, 2mg P/0.625mg I

***Preterax (SER/STO); 1.0003 per Tab. (30)**

Tablet, 4mg P/1.25mg I

Bi Preterax (SER/STO); 1.1373 per Tab. (30)*66. PETHIDINE HYDROCHLORIDE (N)***Therapeutic Category:* Narcotic analgesic.*Indications:* Moderate to severe acute pain. Obstetric analgesia.*Caution/Side Effects:* See under morphine but less constipating.*Dose Range:* **Oral:** 50-150mg every 4 hours. **s.c. or i.m.:** 25-100mg, repeated after 4 hours. By slow i.v. 25-50mg, repeated every 4 hours. *See protocol pg. ix section 2 (vii).**Preparations:*

Tablet, 50mg

***Pethidine (MTP/COL); 0.3768 per Tab. (112)**

Inj. 50mg/ml; 2.15 ml Amp.

Pethidine (MTP/COL); 0.8500 per Amp.*67. PHENAZOPYRIDINE HYDROCHLORIDE***Indications:* Urinary tract pain.*Caution/Side Effects:* Renal and hepatic impairment. May colour urine red (harmless). May stain soft contact lenses.*Dose Range:* 600mg daily in divided doses every 8 hours with food. **THE MAXIMUM DURATION OF THERAPY IS TWO (2) DAYS.***Preparations:*

Tablet, 100mg

***Phenazopyridine (CPC/BKL); 0.3587 per Tab. (12)**

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

68. PINDOLOL(B)

Therapeutic Category: Non-selective Beta-Adrenergic Blocker.

Indications: Hypertension. Non-selective beta-adrenergic blocking agent with intrinsic sympathomimetic activity.

Caution/Side Effects: Risk of bronchospasm and peripheral vasoconstriction are decreased because of drug's significant intrinsic sympathomimetic activity. Less bradycardia, Common CNS effects: dizziness, fatigue and insomnia. *c.f. prescribing in renal disease p. 34.*

Dose Range: Angina: 2.5-5mg daily initially then 10-40mg daily in divided doses.

Hypertension: 5mg twice daily to a maximum of 60mg in 2-3 doses.

Preparations:

Tablet, 5mg

***Apo-Pindolol (APO/COL); 0.0606 per Tab. (240)**

69. PIRIBEDIL

Therapeutic Category: Dopaminergic receptor agonist.

Indications: Cerebral Vascular Insufficiency, Dementia, Parkinson's disease.

Caution/Side Effects: Nausea and vomiting, dizziness. Do not use with MAOI's. Side Effects seen in patients with Parkinson's Disease include: Hallucinations, depression, delirium, exacerbation of mania.

Dose Range: Cerebral Vascular Insufficiency and Dementia: 50mg daily with the main meal. Parkinson's Disease: 50mg-250mg daily in divided doses.

Preparations:

Tablet, Retard, 50mg

***Trivastal 50 Retard (SER/STO); 0.7320 per Tab. (120)**

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***70. PIROXICAM**

Therapeutic Category: Nonsteroidal anti-inflammatory drug.

Indications: Relief of pain and inflammation in rheumatic and musculo-skeletal disorders. Acute gout.

Caution/Side Effects: Gastro-intestinal irritation.

Dose Range: 20mg daily. *See protocol pg. ix section 3.*

Preparations:

Capsule, 20mg

***Apo-Piroxicam (APO/COL); 0.1017 per Cap. (30)**

71. QUINAPRIL(B)

Therapeutic Category: Non-sulhydryl ACE Inhibitor.

Indications: Hypertension. Congestive heart failure.

Caution/Side Effects: Headache, fatigue, nausea, dizziness, cough and hypotension. Avoid in the 2nd and 3rd trimesters of pregnancy. *c.f. prescribing in renal disease p. 35.*

Dose Range: **Hypertension:** Initially 10-20mg once daily to 20-80mg in one or two doses. Maximum of 80mg daily. **CHF:** 5mg twice daily initially to 20-40mg twice daily. *See protocol pg. xii section 6.*

Preparations:

Tablet, 5mg

***Accupril (PFI/SBI); 0.3527 per Tab (60)**

Tablet, 10mg

***Quinapril (DRL/BKL); 0.2891 per Tab. (60)**

Tablet, 20mg

***Quinapril (DRL/BKL); 0.5023 per Tab. (120)**

SCHEDULE – *Cont'd*

(*Paragraph 3*)

PART I – *Cont'd*

(*Paragraph 3(a)*)

72. QUINIDINE SULPHATE

Therapeutic Category: Antiarrhythmic Agent Class 1A.

Indications: Class I, III. Used to treat and prevent PAT, PVC's, atrial dysarrhythmias; to maintain sinus rhythm after cardioversion.

Caution/Side Effects: Common when dose exceeds 3g/24 hours, but may occur at any level. Diarrhoea, cinchonism and general muscle weakness, allergic manifestations, cardiac effects ranging from ectopic beats to ventricular fibrillation, cardiac arrest or failure.

Dose Range: Adult: 200-400mg three or four times daily.

Preparations:

Tablet, 200mg

***Quinidine (MUP/BKL); 0.7605 per Tab.**

73. RAMIPRIL/HYDROCHLORTHIAZIDE (B)

Therapeutic Category: ACE Inhibitor combined with thiazide diuretic.

Indications: Hypertension, CHF.

Caution/Side Effects: As for Captopril. The fixed dose combination is not indicated for initial therapy and is not suitable for titration.

Dose Range: One tablet daily. *See protocol pg. xii section 6.*

Preparations:

Tablet, 2.5mg R/12.5mg H

***Tritace HCT (SFA/COL); 0.6955 per Tab. (30)**

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))***74. RESERPINE (B)***Therapeutic Category:* Rauwolfia alkaloid.*Indications:* Hypertension.*Caution/Side Effects:* Lethargy, nasal stuffiness, weight gain, diarrhoea, drowsiness, mental depression with suicidal tendencies, decreased libido, nightmares, activation of peptic ulcers. With larger doses, extrapyramidal (parkinson like syndrome). *See protocol pg. xii section 6.**Dose Range:* 20mg/kg daily in 1 or 2 divided doses to a maximum of 0.25mg/day.*Preparations:*

Tablet, 0.25mg

*Consult the BDS for Supplies. (No Offers to Supply)***75. REPAGLINIDE (B)***Therapeutic Category:* Meglitinide hypoglycemic agent.*Indications:* Treatment of Type 2 Diabetes Mellitus as monotherapy or with metformin. Stimulates pancreatic insulin secretion in response to a glucose load. (e.g) after a meal.*Caution/Side Effects:* Hypo and hyperglycemia, diarrhea, dyspepsia, nausea, urticaria. It should not be used in patients with Type 1 diabetes. *Drug Interactions:* Drug which increase the risk of hypoglycemia: Gemfibrozil, Guar Gum, Psyllium and St. John's Wort. Do not use in combination with Sulfonylureas.*Dose Range:* 0.5mg - 4mg two to four times daily with each meal. Maximum of 16mg/day. *See protocol pg. xiii section 9.**Preparations:*

Tablet, 1mg

***Novonorm (NOV/COL); 0.4933 per Tab. (120) (Public Sector use only).**

Tablet, 2mg

***Novonorm (NOV/COL); 0.6100 per Tab. (120) (Public Sector use only).**

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

76. RESERPINE-BENDROFLUAZIDE (B)

Therapeutic Category: Rauwolfia alkaloid combined with a diuretic.

Indications: Hypertension.

Caution/Side Effects: Avoid in diabetics. Dry mouth, nasal stuffiness. *See protocol pg. xii section 6.*

Dose Range: One tablet daily.

Preparations:

Tablet, Reserpine 0.15mg/Bendrofluazide 5mg

***Combezone B (CAR/COL); 0.1255 per Tab. (30)**

Tablet, Reserpine 0.15mg/Bendrofluazide 2.5mg

***Combezone L (CAR/COL); 0.1255 per Tab. (30)**

77. RESERPINE-CLOPAMIDE-DIHYDROERGOCRISTINE (B)

Therapeutic Category: Combination antihypertensive.

Indications: Hypertension.

Caution/Side Effects: Avoid in diabetics. Contains clopamide which is a thiazide diuretic. *See protocol pg. xii section 6.*

Dose Range: One tablet daily.

Preparations:

Tablet, 0.1mg R/5mg C/0.5mg D

***Brinerdin (NVS/COL); 0.2422 per Tab. (30)**

SCHEDULE – Cont'd

(Paragraph 3)

PART I – Cont'd

(Paragraph 3(a))

78. ROPIVACAINE

Therapeutic Category: An amide-type local anesthetic.

Indications: Production of local or regional anesthesia during surgery, for postoperative pain management, and for use during obstetrical procedures.

Caution/Side Effects: Hypotension, tachycardia, backache, shivering, urinary retention, nausea and vomiting.

Dose Range: 0.5%-1% has been used in dosages of 5-250mg depending upon the procedure. For labour pain management, ropivacaine 0.2% has been administered in a dosage of 20-40mg initially with a 12-28mg/hour continuous infusion. For postoperative pain management ropivacaine 0.2%-0.5% in a dosage of 2-200mg has been administered depending upon the infusion type. Dose reductions should be considered in liver disease.

Preparations:

Inj., 2mg/ml; 10ml vial

Consult the BDS for Supplies. (No Offers to Supply)

Inj., 7.5mg/ml; 10ml vial

Consult the BDS for Supplies. (No Offers to Supply)

Inj., 10mg/ml; 10ml vial

Consult the BDS for Supplies. (No Offers to Supply)

79. ROSUVASTATIN

Therapeutic Category: HMG-CoA reductase inhibitor (statin).

Indications: Rosuvastatin has been approved for treatment of primary hypercholesterolemia, mixed dyslipidemia, hyper-triglyceridemia, and homozygous familial hyper-cholesterolemia. It has produced greater reductions in low-density lipoprotein (LDL)-cholesterol than atorvastatin, simvastatin, and pravastatin.

Caution/Side Effects: Headache, asthenia, upper respiratory infections, gastrointestinal symptoms, and myalgia have been reported; myopathy has occurred rarely. *See protocol pg. x section 5.*

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Dose Range: Adult: 5-40mg orally once daily, with starting doses of 5-20mg once daily. Doses may be titrated to 40mg/day in those who do not meet their lipid lowering goals on 20mg/day. Dose adjustments are suggested for patients with severe renal impairment and those receiving concomitant cyclosporine or gemfibrozil. *See protocol pg. x section 5.*

Preparations:

Tablet, 5 mg

***Crestor (AZN/BRY); 1.5936 per Tab. (30)**

Tablet, 10 mg

***Crestor (AZN/BRY); 1.5936 per Tab. (30)**

Tablet, 20mg

***Crestor (AZN/BRY); 2.1396 per Tab. (30)**

80. S-AMLODIPINE/ATORVASTATIN

Therapeutic Category: HMG-COA Reductase Inhibitor/Calcium Channel Blocker Combination.

Indications: Dyslipidemias with hypertension and stable angina.

Caution/Side Effects: Use cautiously in patients with liver disease, pregnancy and lactation. Avoid in persons with acute myocardial infarction, cardiac dysrhythmia, rhabdomyolysis.

NOTE: S-Amlodipine is the S-enantiomer of amlodipine. It is found to be equal in its effect and tolerably compared to racemate amlodipine. It provides the active CCB component at half the dose. It has a longer plasma half-life and less incidence of peripheral oedema. S-Amlodipine/Atorvastatin 2.5/10mg is equivalent to Amlodipine/Atorvastatin 5mg/10mg. S-Amlodipine/Atorvastatin 5/10mg is equivalent to Amlodipine/Atorvastatin 10/10mg.

Dose Range: 2.5mg-5mg daily.

Preparations:

Tablet 2.5mg AB/10mg AC

***Numlotor (EMC/COL); 0.1749 per Tab. (30)**

SCHEDULE – *Cont'd**(Paragraph 3)*PART I – *Cont'd**(Paragraph 3(a))*

Tablet 5mg AB/10mg AC

Numlotor-5(EMC/COL); 0.2557 per Tab. (30)*81. SIMVASTATINE/EZETIMIBE***Therapeutic Category:* Antihyperlipidemic and Cholesterol Absorption Inhibitor.*Indications:* Hypercholesterolemia.*Caution/Side Effects:* Drug-induced myopathy, hepatitis, increased liver function test, rhabdomyolysis. Avoid with grapefruit juice. *See protocol pg. x section 5.**Dose Range:* One tablet daily. *See protocol pg. x section 5.**Preparations:*

Tablet, 10mg E/10mg S

***Vytorin (MSD/STO); 1.6150 per Tab. (30)**

Tablet, 10mg E/20mg S

***Vytorin (MSD/STO); 1.6150 per Tab. (30)**

Tablet, 10mg E/40mg S

***Vytorin (MSD/STO); 2.4221 per Tab. (30)**

Tablet, 10mg E/80mg S

Vytorin (MSD/STO); 2.4221 per Tab. (30)*82. SULINDAC***Therapeutic Category:* Nonsteroidal anti-inflammatory drug.*Indications:* Pain and inflammation of rheumatic and other musculoskeletal disorders, where a longer acting non-steroidal Anti-inflammatory drug is required or allergy to first drugs (aspirin and indomethacin).*Caution/Side Effects:* Gastro-intestinal irritation.

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

Dose Range: 100-200mg twice daily with meals. *See protocol pg. ix section 3.*

Preparations:

Tablet, 200mg

***Apo-Sulin (APO/COL); 0.2180 per Tab. (28)**

83. TELMISARTAN/HYDROCHLORTHIAZIDE (B)

Therapeutic Category: Angiotensin II receptor antagonist.

Indications: For the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Caution/Side Effects: Headache, diarrhoea, fatigue and nausea.

Dose Range: Initially one tablet daily maintain at 1-2 tablets daily. *See protocol pg. xii section 6.*

Preparations:

Tablet, 80mg T/12.5mg H

***Micardis Plus (BOE/STO); 1.1900 per Tab. (30)**

Tablet, 80mg T/25mg H

***MicardisPlus (BOE/STO); 1.1900 per Tab. (30)**

84. TENOXICAM

Therapeutic Category: Nonsteroidal anti-inflammatory drug.

Indications: Treatment of rheumatoid, arthritis, osteoarthritis and ankylosing spondylitis.

Caution/Side Effects: G.I. distress (nausea, epigastric pain), headache, dizziness, edema, skin rash.

Dose Range: 20mg tablet daily. *See protocol pg. ix section 3.*

SCHEDULE – Cont'd

(Paragraph 3)

PART I – Cont'd

(Paragraph 3(a))

Preparations:

Tablet, 20mg

Apo-Tenoxicam (APO/COL); 0.6055 per Tab. (14)*85. TERBUTALINE(B)***Therapeutic Category:* Sympathomimetic agent with beta agonist activity.*Indications:* Treatment of bronchospasm in asthma, bronchitis and chronic obstructive pulmonary disease.*Caution/Side Effects:* Headache, nervousness tremor, tachycardia, seizures. Palpitations, angina, insomnia, hyperglycemia, lipid abnormalities, hypotension.*Dose Range:* **Inhaled doses:** 0.5mg every 6 hours. **SC:** 0.25mg initial repeat in 15-30 mins if necessary to a maximum of 0.5mg in 4 hour period.*Preparations:*

Respiratory Solution, 2.5mg/ml; 2ml Amp

Consult the BDS for Supplies. (No Offers to Supply)

Inj., 0.5mg/ml; 1ml vial

*Consult the BDS for Supplies. (No Offers to Supply)***86. TIAPROFENIC ACID***Therapeutic Category:* Nonsteroidal anti-inflammatory drug.*Indications:* Osteoarthritis, rheumatoid arthritis and acute pain from surgery or trauma.*Caution/Side Effects:* Nausea, vomiting, epigastric pain, dizziness, drowsiness.*Dose Range:* 300mg twice a day. **Tablets should be taken with meals and plenty of fluids. See protocol pg. ix section 3.***Preparations:*

Tablet, 300mg

***Apo-Tiaprofenic (APO/COL); 0.6540 per Tab. (28)**

SCHEDULE – *Cont'd*

(Paragraph 3)

PART I – *Cont'd*

(Paragraph 3(a))

87. TINZAPARIN

Therapeutic Category: Low Molecular weight heparin.

Indications: See Heparin Sodium.

Caution/Side Effects: See Heparin Sodium.

Dose Range: Prevention of DVT in surgical patients. 3500 IU 2 hours prior to surgery and then once daily for 7-10 days.

Preparations:

Inj. 3500 Units per vial

Consult the BDS for Supplies. (No Offers to Supply)

Inj. 4500 Units per vial

Consult the BDS for Supplies. (No Offers to Supply)

88. TOLBUTAMIDE(B)

Therapeutic Category: Short acting sulfonylurea.

Indications: Diabetes mellitus, mature onset, without ketosis; when dietary control fails. It is metabolised in the liver and has a much shorter half-life (4-8 hours) than chlorpropamide (24-48 hours); it is therefore preferable in the elderly and those with renal impairment.

Caution/Side Effects: Hypoglycemia, nausea, heartburn, rashes. Half life may be prolonged by some drugs, e.g. phenytoin and sulfonamides.

Dose Range: 500-1.5g to a maximum of 2g daily in divided doses. *See protocol pg. xiii section 8.*

Preparations:

Tablet, 500mg

***Apo-Tolbutamide (APO/COL); 0.0578 per Tab. (240)**

SCHEDULE – Cont'd

(Paragraph 3)

PART I – Cont'd

(Paragraph 3(a))

89. TRIAMCINOLONE-ECONAZOLE*Indications:* Treatment of inflammatory dermatoses; eczema.*Caution/Side Effects:* **Contains a steroid. Do not use for more than 4 weeks.**
*See protocol pg. x section 4.**Dose Range:* Apply to affected skin area twice daily; rub in gently. **Use sparingly.***Preparations:*

Cream, 1% Econazole/1% Triamcinolone; 15g tube.

Pevisone (JAC/STO); 9.0200 per Tube. (2 Tubes)*90. TRIAMCINOLONE-HYDROCORTISONE***Indications:* Treatment of inflammatory dermatoses; eczema.*Caution/Side Effects:* **Contains a steroid. Do not use for more than 4 weeks.** *See protocol pg. x section 4.**Dose Range:* Apply to affected skin area twice daily; rub in gently. **Use sparingly.***Preparations:*

Cream, 15g

Triacomb B (PDN/PHA); 2.9600 per Tube. (2 Tubes)*91. TRIAMTERENE-HYDROCHLORTHIAZIDE(B)***Therapeutic Category:* Potassium sparing diuretic combined with a thiazide diuretic.*Indications:* See Amiloride - Hydrochlorthiazide.*Caution/Side Effects:* See Amiloride - Hydrochlorthiazide.*Dose Range:* Usual starting dose is one tablet daily with meals.*Preparations:*

Tablet, 50mg T/25mg H

***Apo-Triazide (APO/COL); 0.0388 per Tab. (60)**

SCHEDULE – Cont'd

(Paragraph 3)

PART I – Cont'd

(Paragraph 3(a))

92. TRIBENOSIDE

Indications: Chronic venous insufficiency.

Caution/Side Effects: Treatment should be from 6 weeks to 3 months after which the condition should be evaluated.

Dose Range: 400mg twice daily. *See protocol pg. xvi section 16.*

Preparations:

Capsule, 400mg

***Glyvenol (NVS/COL); 0.5280 per Cap. (90)**

93. TRIPROLIDINE-PSEUDOEPHEDRINE

Therapeutic Category: Antihistamine/DeCongestant Combination.

Indications: Symptoms associated with allergy and common cold e.g. hay fever, rhinitis.

Caution/Side Effects: Drowsiness, nervousness, excitation. See general information on antihistamines on page 87.

Dose Range: **Adult:** 1 tablet every 4-6 hours. **Pediatric 4 months-2 years:** ¼ teaspoonful every 4-6 hours. **2-4 years:** ½ teaspoonful every 4-6 hours. **4-6 years:** ¾ teaspoonful every 4-6 hours. *See protocol pg. xiv section 12.*

Preparations:

Syrup 1.25mg T/30mg P per ml

***Silafed (RIM/PHA); 0.0408 per ml. (120mls)**

94. VALSARTAN/HYDROCHLORTHIAZIDE (B)

Therapeutic Category: A nonpeptide angiotensin II receptor antagonist.

Indications: Treating essential hypertension. Valsartan is indicated for the treatment of heart failure in patients who are intolerant of angiotensin - converting enzyme (ACE) inhibitors. The drug is being studied for use in left ventricular hypertrophy.

SCHEDULE - *Cont'd**(Paragraph 3)*PART I - *Concl'd**(Paragraph 3(a))*

Caution/Side Effects: Headache, dizziness, viral infection, upper respiratory tract infection, cough, diarrhea, drowsiness, rhinitis, sinusitis, backache, stomach ache, nausea, pharyngitis and joint pain. The drug is contraindicated in pregnancy. *See protocol pg. xii section 6.*

*Dose Range: **Hypertension:*** The recommended oral dose is 80mg once daily, with or without food. The dose may be increased to 160mg daily if initial response is insufficient. Maximum effect is observed after 4 weeks of therapy. **Heart Failure:** Initial dose is 40mg twice daily, with titration to 80-160mg twice daily as tolerated. *See protocol pg. xii section 6.*

Preparations:

Tablet, 80mg Valsartan/12.5mg HCTZ

***Codiovan (NVS/COL); 1.1493 per Tab. (30)**

Tablet, 160mg Valsartan/12.5mg HCTZ

***Codiovan (NVS/COL); 1.1493 per Tab. (30)**

Tablet, 160mg Valsartan/25mg HCTZ

***Codiovan (NVS/COL); 1.1493 per Tab. (30)**

Tablet, 320mg Valsartan/12.5mg HCTZ

***Codiovan (NVS/COL); 1.1493 per Tab.**

Tablet, 320mg/ Valsartan/25mg HCTZ

***Codiovan (NVS/COL); 1.1493 per Tab.**

SCHEDULE – *Concl'd*

(Paragraph 3)

PART II

(Paragraph 3(b))

*The Drug to be inserted into the 30th Edition of the
Barbados National Drug Formulary*

BRIMONIDINE/TIMOLOL

Indications: Reduction of intraocular pressure (IOP) in patients with progression of glaucoma or ocular hypertension, who are insufficiently responsive to topical B. blockers.

Caution/Side Effects: Ocular stinging, ocular pain, pruritus, headache, conjunctival hyperemia, and conjunctival inflammation.

Dose Range: One drop into the affected eye twice a day.

Preparations:

0.2% B/0.5% T Eye Drop

***COMBIGAN (ALL/COL); 32.2900 per Bottle (I)**

Made by the Minister this 27th day of June, 2011.

DONVILLE O. INNISS
Minister responsible for Health.